Kitazawa, Takehisa
Shima, Midori
Article History
Received: 18 July 2018
Revised: 7 September 2018
Accepted: 10 September 2018
First Online: 22 October 2018
Compliance with ethical standards
:
: MS receives research Grants and/or (consulting) honoraria from Chugai, F. Hoffmann-La Roche, Baxalta, Bayer, BioMarine, Bioverativ, CSL Behring, Novo Nordisk, Pfizer, Sanofi and Sysmex, and is engaged in clinical studies sponsored by Chugai and Roche. TK is an employee of Chugai and possesses Chugai stock. TK and MS are inventors of the patents relating to emicizumab.